Abstracts tagged "autoantibodies"

Abstract Number: 2579 • 2012 ACR/ARHP Annual Meeting
Novel Autoantibodies to 14-3-3 Eta Are Highly Specific for Rheumatoid Arthritis
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, Vivian P. Bykerk⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Serum 14-3-3 eta, a protein biomarker that is differentially expressed in rheumatoid arthritis (RA), has been reported to add incrementally to rheumatoid factor (RF)…
Abstract Number: 1688 • 2012 ACR/ARHP Annual Meeting
Evolution of Preclinical Autoimmunity in Individuals At Risk for Development of Rheumatoid Arthritis
Hani S. El-Gabalawy¹, David B. Robinson¹, Irene Smolik¹, Donna M. Hart¹, Elizabeth D. Ferucci², Marianna M. Newkirk³, Marvin J. Fritzler⁴, Catriona Cramb⁵, Jeremy Sokolove⁶ and William H. Robinson⁷, ¹Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ²Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ³Medicine, McGill University Health Centr, Montreal, QC, Canada, ⁴Medicine, University of Calgary, Calgary, AB, Canada, ⁵CCSR 4135 Immunology Rheumatol, Stanford University, Palo Alto, CA, ⁶Medicine, Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Rheumatoid arthritis (RA) is prevalent, severe, and predominantly seropositive in many North American Native (NAN) populations. We have shown a strong tendency towards familial…
Abstract Number: 758 • 2012 ACR/ARHP Annual Meeting
Cutaneous Ulceration in Dermatomyositis: Association with MDA-5 and Interstitial Lung Disease
Neera Narang¹, Livia Casciola-Rosen², Antony Rosen², David Fiorentino³ and Lorinda Chung⁴, ¹Stanford Univ Medical Center, Stanford, CA, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Rheumatology, Stanford Univ Medical Center, Palo Alto, CA
Background/Purpose: Dermatomyositis (DM) is a multisystem autoimmune disease that affects the muscles and skin and can be associated with malignancy or interstitial lung disease (ILD). …
Abstract Number: 71 • 2012 ACR/ARHP Annual Meeting
The Association Between Preclinical Markers for Cardiovascular Disease and Rheumatoid Arthritis-Related Autoantibodies in First-Degree Relatives without Rheumatoid Arthritis
Ryan W. Gan¹, Jan M. Hughes-Austin², Kevin D. Deane³, Elaine M. Urbina⁴, Peter K. Gregersen⁵, Michael H. Weisman⁶, V. Michael Holers⁷ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Epidemiology, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Preventive Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and immune dysregulation, including the presence of autoantibodies and elevated inflammatory markers in subjects with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].